LONDON (dpa-AFX) - British drug major GSK plc (GSK, GSK.L) announced Monday the first global data for risvutatug rezetecan (Ris-Rez), its investigational B7-H3-targeted antibody-drug conjugate (ADC), in patients with relapsed extensive-stage small cell lung cancer or ES-SCLC.
The company noted that the results from the phase Ib dose-optimisation portion of the EMBOLD PanTumour-101 trial showed positive anti-tumour activity and a manageable safety profile. The data adds to recently reported positive phase III data in patients with SCLC in China.
Ris-Rez is a novel investigational antibody-drug conjugate targeting the B7-H3 protein, which is highly expressed in more than 10 solid tumour types.
EMBOLD PanTumour-101 (NCT06551142), a global, open-label phase Ia/b study, evaluates the safety, tolerability and clinical activity of Ris-Rez monotherapy in adult patients with advanced or metastatic solid tumours.
In the trial, Ris-Rez achieved a confirmed objective response rate or ORR of 61% among evaluable patients at the 8 mg/kg dose, compared with 32% at the 6 mg/kg dose.
The company plans to present the findings in a poster session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
Hesham Abdullah, Senior Vice President, Global Head of Oncology, R&D, GSK said, 'Today's first global data for Ris-Rez build on the statistically significant overall survival benefit recently reported in Hansoh's pivotal Chinese trial. As the data for Ris-Rez continues to grow, we remain focused on accelerating development in extensive-stage small cell lung cancer, where patients often relapse quickly and urgently need more treatment options.'
For More Such Health News, visit rttnews.com
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
